EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

Neuro-oncology
Enrico FranceschiAlba Ariela Brandes

Abstract

The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in this setting. The study was designed as multicenter, randomized phase II trial, preceded by a lead-in safety phase. The safety component reported here, which also investigated pharmacokinetics and preliminary clinical activity, required expansion and is therefore considered a phase I part to establish a recommended dosing regimen of the combination of CCNU (90-110 mg/m(2)) and dasatinib (100-200 mg daily). Overall, 28 patients were screened, and 26 patients were enrolled. Five dose levels were explored. DLTs, mainly myelosuppression, occurred in 10 patients. Grade 3 or 4 neutropenia was recorded in 7 patients (26.9%) and thrombocytopenia in 11 patients (42.3%). No significant effect of CCNU coadministration on dasatinib pharmacokinetics was found. Median progression-free survival (PFS) was 1.35 months (95% confidence interval: 1.2-1.4) and 6-month PFS was 7.7%. In this phase I study of recurrent glioblastoma patients, the...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ Gregory Cairncross
Aug 12, 2004·Neurology·M C Y de WitMartin J van den Bent
Mar 11, 2005·The New England Journal of Medicine·Roger StuppNational Cancer Institute of Canada Clinical Trials Group
Jul 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evanthia GalanisNorth Central Cancer Treatment Group
Mar 23, 2006·Journal of Neuro-oncology·Caren V LundBrian P Eliceiri
Mar 22, 2007·Expert Opinion on Therapeutic Targets·Andrew S Chi, Patrick Y Wen
Sep 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roger StuppArnab Chakravarti
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba Ariela BrandesMario Ermani
Oct 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric RaymondEuropean Organisation for Research and Treatment of Cancer Brain Tumor Group Study
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J van den BentThierry Gorlia
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Nov 12, 2009·Brain Pathology·David CapperAndreas von Deimling
Dec 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alba Ariela BrandesMartin J van den Bent
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickHoward A Fine
Feb 18, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickRoger Stupp
Feb 16, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Roger StuppAlba Ariela Brandes
Mar 13, 2012·Journal of Neuro-oncology·David A ReardonHenry S Friedman

Citations

Feb 11, 2014·Current Oncology Reports·Mohamed Ali Hamza, Mark R Gilbert
Sep 16, 2014·Seminars in Radiation Oncology·John P Kirkpatrick, John H Sampson
Oct 22, 2013·Oncogene·A DudleyK Petrecca
May 7, 2015·Pharmacology & Therapeutics·Constantinos Alifieris, Dimitrios T Trafalis
Mar 27, 2015·Neoplasia : an International Journal for Oncology Research·Hongxiang WangJuxiang Chen
Feb 12, 2015·Clinical Pharmacology and Therapeutics·K E ParrishW F Elmquist
Nov 21, 2014·Journal of Neuro-oncology·Jennie W TaylorAndrew S Chi
May 14, 2016·Expert Opinion on Investigational Drugs·Verena StaedtkeJohn Laterra
Dec 19, 2017·Journal of Drug Targeting·Khaled GreishHayley Nehoff
Jun 29, 2018·Expert Opinion on Therapeutic Patents·Matthew HarrisDavid Bailey
Sep 26, 2013·Journal of Neuro-oncology·Boqian SunDun Wei
Aug 18, 2020·Expert Review of Anticancer Therapy·Vincenzo Di NunnoAlba Ariela Brandes
Oct 28, 2018·International Journal of Molecular Sciences·Puja Sharma, Waldemar Debinski
Jun 4, 2020·International Journal of Molecular Sciences·Filippo TorrisiSamuel Valable
May 21, 2019·Expert Review of Neurotherapeutics·Candice D CarpenterVinay K Puduvalli
Jul 4, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marta BaroJoseph Contessa
Jan 25, 2021·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Alicia TosoniAlba Ariela Brandes
Dec 31, 2020·Cancers·Cristina BirzuGiuseppe Lombardi

Related Concepts

(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
Antineoplastic Chemotherapy Protocols
Brain Tumor, Recurrent
Glioblastoma Multiforme
Belustine
Neoplasm Recurrence, Local
Pyrimidines
Thiazoles
Progression-Free Survival
Maximum Tolerated Dose

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Roger StuppESMO Guidelines Working Group
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Thierry GorliaMartin J van den Bent
Expert Review of Anticancer Therapy
Roger StuppMichael Weller
© 2021 Meta ULC. All rights reserved